Aurobindo Pharma, a mid-size pharmaceutical company, witnessed a fall on Wednesday on reports that the US drug regulator (USFDA) raised quality issues at Unit 12 manufacturing facility of the company.
 
Aurobindo Pharma's Unit 12 is mainly used to manufacture drugs which are exported to US. The unit manufacturers products like Tazobactam and Piperacilin.

Shares of Aurobindo Pharma are trading at Rs 739.15, down Rs 9.25, or 1.24% at the Bombay Stock Exchange (BSE) on Wednesday at 10:33 a.m.

The scrip has touched an intra-day high of Rs 744 and low of Rs 718. The total volume of shares traded at the BSE is 45,673.